The International Rett Syndrome Foundation (IRSF) has awarded a research grant to Neurolixis Inc. to study its clinical asset, NLX-101, in animal models of Rett syndrome. NLX-101 reverses breathing difficulties in transgenic mice that exhibit the symptoms of Rett syndrome (see publication by Levitt et al.). The new grant will support investigation of NLX-101 in cardiorespiratory tests by a physiology team at the University of Bristol, UK. NLX-101 displays 'biased agonism' at serotonin 5-HT1A receptors located in brain regions that control cognition and mood, as well as breathing. If the new studies are successful, Neurolixis aims to advance NLX-101 to proof-of-concept Phase 2 clinical trials.